ABSTRACT
INTRODUCTION
Suicide genes encode enzymes that convert nontoxic prodrugs into cytotoxic drugs. For example, herpes simplex virus thymidine kinase ( HSV-TK ) is capable of monophosphorylating the prodrug ganciclovir (GCV) into P-GCV, which can subsequently be phosphorylated to the cytotoxic drug P 3 -GCV by endogenous TK (8) . This capability of HSV-TKhas been shown to be of therapeutic use in numerous animal models of cancer gene therapy. The HSV-TK /GCV system is therefore applied in a number of clinical gene therapy trials ( http:// www.wiley.co.uk/genet herapy/clinical/ ).
More recently, synergy between HSV-TK /GCV treatment and other gene therapy approaches has been demonstrated (1, 7, 10) . Considering these results, we decided to generate a retroviral plasmid for combination suicide gene therapy. We constructed a retroviral vector plasmid containing a fusion gene of HSV-TKand Streptoalloteichus hindustanus ble( Sh-ble ) (5) driven by an internal simian virus 40 (SV40) early promoter. This fusion gene gives rise to Zeocin ™ (Invitrogen, Groningen, The Netherlands) resistance, allowing the selection of transduced cells, and GCV sensitivity for therapeutic/safety purposes. Importantly, the resulting combination plasmid, pCC1, contains an MCS downstream of the 5 ′ long terminal repeat (LTR) promoter of the Moloney murine leukemia virus, allowing the insertion of a variety of therapeutic genes. To test the functionality of pCC1, the rtIL-2 cDNA was inserted in the sense direction in this MCS. GCV cytotoxicity and rtIL-2 secretion were analyzed on wild-type OV-Ca rat ovarian carcinoma cells, OV-Ca cells transduced with pCC1 and OV-Ca cells transduced with pCC1 rtIL-2 S.
MATERIALS AND METHODS

Cloning of pCC1 and pCC1 rtIL-2
The retroviral plasmid pCC1 was cloned using standard techniques (6) . Briefly, the cassette containing the HSV-TK::Sh-blefusion gene was obtained by enzymatic digestion of plasmid pUT102 (CAYLA, Toulouse, France) with Sca I and Cla I. This fragment was ligated into the Hin dIII (rendered blunt using Klenow DNA polymerase) and Cla I sites of the retroviral plasmid pBabe puro (9) . The SV40 polyA sequence from the HSV-TK::Shble cassette was subsequently removed using restriction digestion with Cla I and Csp I, followed by self-closure of the plasmid, resulting in the retroviral plasmid pCC1 (6043 bp).
The rtIL-2 cDNA was inserted in the sense direction in the MCS of pCC1 by digestion of pT7T3 19 U rtIL-2 with Eco RI and Sal I and ligation of this cassette in the Eco RI and Sal I sites of pCC1. The rtIL-2 polyA sequence was removed by restriction digestion with Swa I and Sal I. The cut Sal I site was ren -dered blunt, after which the plasmid was closed using T4 DNA ligase. The resulting construct was named pCC1 rtIL-2 S.
All enzymes used were commercially available (Roche Molecular Biochemicals, Meylan, France; Life Technologies, Cergy Pontoise, France and Promega, Charbonnieres, France), and used according to the manufacturers' instructions. Competent INVα F ′ bacteria (Invitrogen) were used for most cloning steps, while non-methylated DNA templates (necessary for some restriction digests) were prepared using competent dam -/dcm -GM2163 (New England Biolabs, Beverly, MA, USA) or DM1 ™(Life Technologies) bacteria.
Cell Culture
Amphotropic ψ -CRIP packaging cells (4) were maintained in DMEM supplemented with 10% heat-inactivated newborn calf serum, 1 mM sodium pyruvate, 100 IU/mL penicillin and 100 µ g/mL streptomycin. OV-Ca rat ovarian carcinoma cells were maintained in DMEM supplemented with 10% heatinactivated fetal bovine serum and sodium pyruvate and antibiotics as above. Cell culture reagents were purchased from Sigma (Saint Quentin Fallavier, France) and Life Technologies, and Falcon ® cell culture plastic was purchased from Becton Dickinson (Le Pont de Claix, France).
Retroviral Infections
Amphotropic ψ -CRIP packaging cells were electroporated in 4 mm cuvettes using an EasyjecT Plus electroporator (EquiBio, Boughton Monchelsea, England, UK) with 30 µ g circular pCC1 or pCC1 rtIL-2 S DNA, running a simple pulse program at 280 V and a capacity of 1500 µ F. The next day, cultures were put under Zeocin selection (166 µ g/mL final). Mixed cultures of ψ -CRIP cells that were electroporated with either pCC1 or pCC1 rtIL-2 S were obtained. Retroviral supernatants of confluent 175 cm 2 culture flasks containing these mixed cultures, ψ -CRIP pCC1 mix and ψ -CRIP pCC1 rtIL-2 S mixture, respectively, were filtered (poresize 0.45 µ m) and used directly for retroviral infection, or stored at -75°C.
To infect OV-Ca cells, 10 mL filtered retroviral supernatant was added to 10 6 cells in a 10 cm culture dish. To enhance infection, polybrene (hexadimethrine bromide; Sigma) was added to a final concentration of 8 µ g/mL.
The next day, the retroviral supernatant was removed, cells were washed with PBS and fresh complete culture medium containing 250 µ g/mL Zeocin was added. Zeocin-resistant OV-Ca clones infected with either supernatant of ψ -CRIP pCC1 mixture cells or ψ -CRIP pCC1 rtIL-2 S mixture cells were obtained and analyzed for GCV cytotoxicity and rtIL-2 secretion.
GCV Cytotoxicity Assays
Cells (grown in the absence of Zeocin) were dislodged using trypsin and dispensed in 96-well plates at 500 cells per well in 100 µ L of complete culture medium. The next day, 100 µ L of 2 ×concentrated solutions of GCV (Cymévan ® ; Roche, Neuilly-sur-Seine, France) in complete culture medium were added. The final GCV concentrations ranged from 0-100 µ g/mL with each concentration assayed in triplicate. (Although the sodium salt of GCV was used, the concentrations refer to the GCV concentration, not the sodium GCV concentration.) Cells were incubated for six days, after which cytotoxicity was quantified using the sulforhodamine B (SRB; Sigma) cytotoxicity assay (12). Absorbance at wavelengths of 540 nm (SRB-specific) and 630 nm (background) was determined using a Multiskan MS platereader (Labsystems, Helsinki, Finland).
Quantification of Rat Interleukin-2 Production
Cells (grown in the absence of Zeocin) were dislodged using trypsin and counted. One million cells were seeded in 10 cm dishes in 10 mL of the appropriate medium. After 24 h, the conditioned medium was collected, filtered through a 0.45 µ m pore-size filter and stored at -20°C. The quantity of rat IL-2 in these conditioned media was determined using the Quantikine ™M rat IL-2 immunoassay (R & D Systems, Abingdon, England, UK) according to the manufacturer's instructions on neat or 1:10 diluted samples. Absorbance (test: 450 nm; reference: 630 nm) was measured on a model MR5000 plateeader (Dynatech, Saint Cloud, France).
RESULTS
Functionality of the HSV-TK::Sh-ble Fusion Gene and Retroviral Sequences of pCC1
The retroviral plasmid pCC1 (Figure 1) contains both a synthetic bacterial promoter (EM-7) and a eukaryotic promoter (SV40 early) that drives the HSV-TK::Sh-blefusion gene, conferring Zeocin resistance to both Escherichia coli bacteria and eukaryotic cells. E. coli bacteria transformed with pCC1 proliferated both on solid lowsalt LB medium and in liquid low-salt LB medium containing Zeocin (data not shown), thus confirming the functionality of the EM-7 promoter and the HSV-TK::Sh-blefusion gene in these bacteria. However, pCC1 also contains the ampicillin resistance gene in the plasmid backbone, and ampicillin selection was used in most cloning steps.
The SV40 early promoter in pCC1 functions equally well because Zeocin resistance was induced in ψ -CRIP packaging cells electroporated with pCC1 or pCC1 rtIL-2 S. Supernatant from both ψ -CRIP pCC1 mix and ψ -CRIP pCC1 rtIL-2 S mixture cells were capable of transferring the Zeocin-resistant phenotype to OV-Ca target cells, showing that functional retroviral particles containing pCC1 or pCC1 rtIL-2 S retroviral RNA were generated (both titers >10 5 cfu/mL; data not shown).
GCV Cytotoxicity Assays
Unmodified OV-Ca cells, OV-Ca pCC1 clone 5 and OV-Ca pCC1 rtIL-2 S clone 6 were incubated for six days with GCV concentrations ranging from 0-100 µ g/mL (0-394 µ M). The cytotoxicity of these GCV concentrations was determined using the SRB assay (11) . The wild-type cells were insensitive to GCV concentrations up to and including 50 µ g/mL (197 µ M), while both OV-Ca pCC1 clone 5 and OV-Ca pCC1 rtIL-2 S clone 6 were sensitive to GCV cytotoxicity at concentrations as low as 0.5 µ g/mL (2.0 µ M) and show-ing similar cytotoxicity curves (IC 50 values of 3.3 and 3.9 µ M, respectively). The level of cytotoxicity of the latter two clones at 0.5 µ g/mL GCV (2.0 µM) is comparable to cytotoxicity at 100 µ g/mL (394 µ M) for the wild-type cells. Gene-modified cells are therefore roughly 200-fold more sensitive to GCV than unmodified cells of this cell line. A further three clones of both OVCa pCC1 and pCC1 rtIL-2 S displayed comparable GCV sensitivity (data not shown). Similar results were obtained with OV-Ca pCC1 or pCC1 rtIL-2 S clones maintained in the absence or presence of Zeocin (data not shown), suggesting the stable transduction of these clones. Figure 2 shows the results of the GCV cytotoxicity assays.
Production of Rat Interleukin-2
Conditioned media of 10 6 wild-type OV-Ca cells or OV-Ca pCC1 clone 5 cells, collected after incubation for 24 h, did not contain detectable rat interleukin-2, as determined by ELISA. In contrast, OV-Ca pCC1 rtIL-2 S clone 6 cells produced readily detectable levels of rtIL-2, on average 146 ng/10 6 cells/24 h. OV-Ca pCC1 rtIL-2 S clone 6 produced the highest level of rtIL-2; three other OV-Ca pCC1 rtIL-2 S clones produced between 2.3 and 4.4 ng/10 6 cells/24 h (data not shown). Maintenance of these clones in the absence or presence of Zeocin did not significantly change the level of rtIL-2 production (data not shown). Figure 3 shows the results of rtIL-2 quantification.
DISCUSSION
In this paper, we have described the cloning and functional testing of a novel retroviral plasmid, pCC1. In this plasmid, based on pBabe puro (9) , the dual function HSV-TK::Sh-blefusion gene (suicide gene/selectable marker) replaces the single function gene puro (selectable marker only). The MCS of pCC1, downstream of the 5 ′ LTR, allows expression of a second gene. In our study, we have introduced the rtIL-2 gene in the sense direction in this site (pCC1 rtIL-2 S). Using retroviral infections into OV-Ca rat ovarian carcinoma cells, we have demonstrated that pCC1 and pCC1 rtIL-2 S clones are about 200-fold more sensitive to GCV cytotoxicity, relative to wild-type OV-Ca cells. Furthermore, OV-Ca pCC1 rtIL-2 S clones produce rtIL-2, in contrast to OV-Ca pCC1 clones and unmodified OV-Ca cells.
The cloning of several genes in the MCS of pCC1 can be envisaged, depending on the target cells. With regard to cancer cells, combination suicide gene therapy has already been shown to be superior to single gene therapy protocols, for example in the case of HSV-TK / GCV and IL-2 in mouse models of oral cancer and metastatic lung cancer (7, 10) . Another successful combination is the association of two suicide genes and 574BioTechniques
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Cancer Research Techniques Figure 2 . GCV cytotoxicity assay. OV-Ca wild-type ( ), OV-Ca pCC1 clone 5 ( v) and OV-Ca pCC1 rtIL-2 S clone 6 ( q) cells were exposed to different concentrations of GCV (X-axis). After six days of GCV exposure, cells were stained with SRB, and absorbance (Y-axis) was measured using a platereader. Data represents mean ± standard deviation of at least three independent assays in triplicate. their prodrugs, HSV-TK /GCV and cytosine deaminase/5-fluorocytosine, resulting in synergy in vitro and in vivo (1) . Apart from targeting cancer cells, pCC1 could be useful as a vector to other cellular targets, delivering a therapeutic gene and providing a safety feature. For example, if the gene encoding a tumor antigen were to be cloned in pCC1, dendritic cells transduced with such a vector could be used as an alternative to dendritic cells loaded with the corresponding proteins because both methods result in anti-tumor immune responses (3). When such pCC1/tumor antigen gene-transduced dendritic cells would provoke side effects after re-administration, the administration of GCV would allow the destruction of the cells causing these effects. In this respect, the HSV-TK /GCV system has already been used for the management of graft vs. host disease in allogeneic, HSV-TKtransduced bone-marrow transplants (2). In conclusion, pCC1 provides a tool for the study of gene therapy approaches using simultaneous expression of a suicide gene and another gene of therapeutic interest.
